• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经生长因子与溴隐亭:人类溴隐亭抵抗性催乳素瘤的序贯疗法

Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.

作者信息

Missale C, Losa M, Boroni F, Giovanelli M, Balsari A, Spano P F

机构信息

Department of Biomedical Sciences and Biotechnology, School of Medicine, University of Brescia, Italy.

出版信息

Br J Cancer. 1995 Dec;72(6):1397-9. doi: 10.1038/bjc.1995.520.

DOI:10.1038/bjc.1995.520
PMID:8519650
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2034102/
Abstract

Nerve growth factor (NGF) administration to athymic mice with transplanted human bromocriptine-resistant prolactinoma, results in the expression of dopamine D-2 receptors in the tumour and restores sensitivity to subsequent treatment with bromocriptine, which then produces normalisation of plasma prolactin and tumour regression. Sequential administration of NGF and bromocriptine thus may be a promising therapy for patients refractory to bromocriptine.

摘要

给移植了人溴隐亭抵抗性催乳素瘤的无胸腺小鼠注射神经生长因子(NGF),会导致肿瘤中多巴胺D-2受体的表达,并恢复对后续溴隐亭治疗的敏感性,进而使血浆催乳素正常化并使肿瘤消退。因此,对溴隐亭难治的患者,序贯给予NGF和溴隐亭可能是一种有前景的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66fc/2034102/7a6d0b95eecf/brjcancer00046-0064-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66fc/2034102/7a6d0b95eecf/brjcancer00046-0064-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66fc/2034102/7a6d0b95eecf/brjcancer00046-0064-a.jpg

相似文献

1
Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.神经生长因子与溴隐亭:人类溴隐亭抵抗性催乳素瘤的序贯疗法
Br J Cancer. 1995 Dec;72(6):1397-9. doi: 10.1038/bjc.1995.520.
2
Nerve growth factor suppresses the transforming phenotype of human prolactinomas.神经生长因子抑制人催乳素瘤的转化表型。
Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7961-5. doi: 10.1073/pnas.90.17.7961.
3
Diagnosis and drug therapy of prolactinoma.泌乳素瘤的诊断与药物治疗
Drugs. 1996 Jun;51(6):954-65. doi: 10.2165/00003495-199651060-00004.
4
Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism.神经生长因子通过自分泌机制控制人催乳素瘤细胞系的增殖和进展。
Mol Endocrinol. 1996 Mar;10(3):272-85. doi: 10.1210/mend.10.3.8833656.
5
Resistance to bromocriptine in prolactinomas.催乳素瘤对溴隐亭的耐药性。
J Clin Endocrinol Metab. 1989 Sep;69(3):500-9. doi: 10.1210/jcem-69-3-500.
6
Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.新型多巴胺能激动剂CV 205-502对溴隐亭抵抗性催乳素瘤患者血浆催乳素水平及肿瘤大小的影响
Clin Endocrinol (Oxf). 1991 Jan;34(1):25-9. doi: 10.1111/j.1365-2265.1991.tb01731.x.
7
Nerve growth factor suppresses the tumoral phenotype of human prolactinomas.
Horm Res. 1997;47(4-6):240-4. doi: 10.1159/000185470.
8
Late development of resistance to bromocriptine in a patient with macroprolactinoma.一例大泌乳素瘤患者对溴隐亭耐药的晚期发生情况。
Horm Res. 1998;49(5):250-3. doi: 10.1159/000023180.
9
Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.卡麦角林治疗溴隐亭抵抗型侵袭性巨大泌乳素瘤。
Endocrine. 2018 Nov;62(2):464-469. doi: 10.1007/s12020-018-1702-5. Epub 2018 Sep 20.
10
A case of large prolactinoma supposed to be cured by bromocriptine therapy.一例被认为经溴隐亭治疗已治愈的大泌乳素瘤病例。
Endocrinol Jpn. 1988 Jun;35(3):503-9. doi: 10.1507/endocrj1954.35.503.

引用本文的文献

1
Cellular interactions in the pituitary stem cell niche.垂体干细胞龛中的细胞相互作用。
Cell Mol Life Sci. 2022 Dec 1;79(12):612. doi: 10.1007/s00018-022-04612-8.
2
Pharmacokinetics and pharmacodynamics of ropinirole in patients with prolactinomas.催乳素瘤患者罗匹尼罗的药代动力学和药效学。
Br J Clin Pharmacol. 2019 Feb;85(2):366-376. doi: 10.1111/bcp.13802. Epub 2018 Nov 22.
3
Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells.抑制SKP2可增强溴隐亭诱导的人催乳素瘤细胞凋亡。

本文引用的文献

1
Nerve growth factor suppresses the transforming phenotype of human prolactinomas.神经生长因子抑制人催乳素瘤的转化表型。
Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7961-5. doi: 10.1073/pnas.90.17.7961.
2
The effect of systemically administered recombinant human nerve growth factor in healthy human subjects.全身性给予重组人神经生长因子对健康人体受试者的影响。
Ann Neurol. 1994 Aug;36(2):244-6. doi: 10.1002/ana.410360221.
3
Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype.
Cancer Res Treat. 2017 Apr;49(2):358-373. doi: 10.4143/crt.2016.017. Epub 2016 Jul 28.
4
Pharmacologic resistance in prolactinoma patients.泌乳素瘤患者的药理耐药性。
Pituitary. 2005;8(1):43-52. doi: 10.1007/s11102-005-5085-2.
5
Dopamine resistance of prolactinomas.催乳素瘤的多巴胺抵抗
Pituitary. 2003;6(1):19-27. doi: 10.1023/a:1026225625897.
6
Neurotrophic factors for the investigation and treatment of movement disorders.用于运动障碍研究与治疗的神经营养因子。
Neurotox Res. 2003;5(1-2):119-38. doi: 10.1007/BF03033377.
7
Brain sites of movement disorder: genetic and environmental agents in neurodevelopmental perturbations.运动障碍的脑区:神经发育扰动中的遗传和环境因素
Neurotox Res. 2003;5(1-2):1-26. doi: 10.1007/BF03033369.
8
Growth factors in pituitary tumors.垂体肿瘤中的生长因子。
Pituitary. 1999 May;1(3-4):153-8. doi: 10.1023/a:1009996712678.
9
Growth factors in the pathogenesis of prolactin-secreting tumors.生长因子在催乳素分泌性肿瘤发病机制中的作用
J Endocrinol Invest. 1998 Jun;21(6):402-11. doi: 10.1007/BF03350778.
10
Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines.神经生长因子可消除人小细胞肺癌细胞系的致瘤性。
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5366-71. doi: 10.1073/pnas.95.9.5366.
Endocrinology. 1994 Jul;135(1):290-8. doi: 10.1210/endo.135.1.8013363.
4
Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors.接受手术治疗的泌乳素分泌型垂体瘤女性的长期随访
J Clin Endocrinol Metab. 1986 Jun;62(6):1296-301. doi: 10.1210/jcem-62-6-1296.
5
Resistance to bromocriptine in prolactinomas.催乳素瘤对溴隐亭的耐药性。
J Clin Endocrinol Metab. 1989 Sep;69(3):500-9. doi: 10.1210/jcem-69-3-500.
6
Giant invasive prolactinoma: a case report and review of nine further cases.巨大侵袭性催乳素瘤:一例报告及另外九例病例回顾
Q J Med. 1990 Mar;74(275):227-38.
7
Management of prolactinomas.催乳素瘤的管理
Clin Endocrinol (Oxf). 1991 Mar;34(3):231-5. doi: 10.1111/j.1365-2265.1991.tb00299.x.
8
Dopamine, the dopamine D2 receptor and pituitary tumours.多巴胺、多巴胺D2受体与垂体肿瘤
Clin Endocrinol (Oxf). 1991 Dec;35(6):455-66. doi: 10.1111/j.1365-2265.1991.tb00928.x.